Form 4: CytomX Therapeutics CEO Sean McCarthy Reports Vesting of Performance Stock Units and Tax-Related Stock Sale
Insider Transaction Report
CytomX Therapeutics CEO Sean McCarthy reported the vesting of 150,000 performance stock units and a subsequent sale of 55,511 shares to cover tax obligations.
Summary
- On June 13, 2025, Sean A. McCarthy, CEO and Director of CytomX Therapeutics, Inc., acquired 150,000 shares of common stock through the vesting of performance stock units (PSUs) that were initially granted on February 2, 2023.
- Following this vesting, Mr. McCarthy's direct beneficial ownership increased to 1,145,195 shares.
- On June 16, 2025, Mr. McCarthy sold 55,511 shares of common stock at a price of $2.6889 per share.
- This sale was conducted solely to satisfy tax or other government withholding obligations related to the PSU vesting.
- After these transactions, Mr. McCarthy's direct beneficial ownership stands at 1,089,684 shares, which includes 488,750 restricted stock units.
- Additionally, 93,158 shares are indirectly beneficially owned through the Sean A. McCarthy 2018 Trust, where he serves as trustee.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions represent a routine vesting of performance stock units and a subsequent sale of shares solely for tax withholding purposes, which is a standard practice for executive compensation and does not indicate a change in company fundamentals or management's view on the stock.
Positives
- The vesting of 150,000 performance stock units indicates that performance targets were met, aligning executive incentives with company performance.
Negatives
- A sale of 55,511 shares, even for tax purposes, reduces the CEO's direct ownership stake in the company.
Future Outlook
NA
Industry Context
This Form 4 filing details routine executive stock transactions for CytomX Therapeutics, a biotechnology company. Such filings are common across the industry as executives manage their equity compensation, and this specific filing does not provide broader industry insights.
Related Party Transactions
- 93,158 shares are indirectly beneficially owned by Sean A. McCarthy through the Sean A. McCarthy 2018 Trust, of which he is the trustee. This constitutes a related party holding.
Stakeholder Impact
- Shareholders: The sale of shares for tax purposes is a routine event and generally has minimal direct impact on shareholders, as it's not a discretionary sale based on market outlook. The vesting of PSUs indicates performance targets were met, which could be seen positively.
Key Dates
| Date | Description |
|---|---|
| 2023-02-02 | Initial grant date of the Performance Stock Units (PSUs) that vested. |
| 2025-06-13 | Date of vesting for 150,000 Performance Stock Units (PSUs) into common stock. |
| 2025-06-16 | Date of sale of 55,511 shares of common stock to satisfy tax obligations. |
| 2025-06-17 | Date the Form 4 filing was signed by Lloyd Rowland, Attorney-in-Fact for Sean A. McCarthy. |
Keywords
CytomX Therapeutics, CTMX, Sean McCarthy, SEC Form 4, Insider Trading, Stock Vesting, Performance Stock Units, PSUs, Stock Sale, Tax Withholding, Executive Compensation, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.